Business Development & Licensing

Business Development

Promotion of Global Business

While our clinical development efforts are based in Japan, we have established nerve centers for clinical development within the overseas subsidiaries: ONO PHARMA USA, INC. (OPUS) and ONO PHARMA UK LTD. (OPUK). Both subsidiaries are pursuing overseas clinical development of our new drug candidates. We also strongly contribute to clinical development efforts in Asia.
We have commenced work to build operations bases in Asia enabling us to market some specialty products such as anticancer drugs overseas. Since establishing ONO PHARMA KOREA CO., LTD. in 2013, and ONO PHARMA TAIWAN CO., LTD. in 2014, both wholly owned subsidiaries of ONO have demonstrated steady progress and received approvals for the anticancer drug OPDIVO for the treatment of several types of cancer, and marketing by the subsidiaries has commenced. We intend to build and strengthen our marketing system with a view to future marketing through our own sales organizations in U.S.A. and Europe.
In cooperation with medical professionals, we will continue to be committed to activities that help to treat patients around the world.